Supplemental Material for Distress Intolerance Moderation of Neurophysiological Markers of Response Inhibition After Induced Stress: Relations With Cannabis Use Disorder

2018 ◽  
Keyword(s):  
Response Inhibition ◽  
Cannabis Use ◽  
Cannabis Use Disorder ◽  
Distress Intolerance ◽  
Induced Stress

scholarly journals Distress intolerance moderation of neurophysiological markers of response inhibition after induced stress: Relations with cannabis use disorder.

2018 ◽  
Vol 32 (8) ◽  
pp. 944-955 ◽  
Author(s):  
Richard J. Macatee ◽  
Brian J. Albanese ◽  
Natania A. Crane ◽  
Sarah A. Okey ◽  
Jesse R. Cougle ◽  
...  
Keyword(s):  
Response Inhibition ◽  
Cannabis Use ◽  
Cannabis Use Disorder ◽  
Distress Intolerance ◽  
Induced Stress

scholarly journals Cognitive control in young adults with cannabis use disorder: An event-related brain potential study

2017 ◽  
Vol 31 (8) ◽  
pp. 1015-1026 ◽  
Author(s):  
David LR Maij ◽  
Ben JM van de Wetering ◽  
Ingmar HA Franken
Keyword(s):  
Cognitive Control ◽  
Response Inhibition ◽  
Performance Monitoring ◽  
Flanker Task ◽  
Event Related Potentials ◽  
Cannabis Use ◽  
Cannabis Use Disorder ◽  
Control Groups ◽  
Related Potentials ◽  
And Performance

Contemporary models of substance use disorders emphasize the role of cognitive control, which has been linked to difficulties in resisting the use of substances. In the present study, we measured two aspects of cognitive control, response inhibition (operationalized by a Go/NoGo Task) and performance monitoring (operationalized by an Eriksen Flanker Task), in a group of young cannabis-use disorder (CUD) patients and compared these functions with two control groups (i.e. a group of cigarette smokers and a group of non-smokers). We employed both behavioural and electrophysiological measures. The results indicate that CUD patients displayed reduced NoGo-P3 event-related potentials compared with non-smoking controls, but not compared with smoking controls. In addition, CUD patients were slower on Go trials than both control groups. No other between-group electrophysiological or behavioural differences were observed. These results seem to suggest that CUD patients have problems related to response inhibition, but performance monitoring seems relatively unaffected.

Genetic Influences in Cannabis Use Disorder and Psychosis: Dopamine and Beyond

2017 ◽  
Vol 22 (42) ◽  
pp. 6392-6396 ◽  
Author(s):  
Amine Benyamina ◽  
Laurent Karila ◽  
Geneviève Lafaye ◽  
Lisa Blecha
Keyword(s):  
Cannabis Use ◽  
Genetic Influences ◽  
Cannabis Use Disorder

scholarly journals Genetic Liability to Cannabis Use Disorder and COVID-19 Hospitalization

2021 ◽  
Author(s):  
Alexander S. Hatoum ◽  
Claire L. Morrison ◽  
Sarah M.C. Colbert ◽  
Evan A. Winiger ◽  
Emma C. Johnson ◽  
...  
Keyword(s):  
Cannabis Use ◽  
Cannabis Use Disorder ◽  
Genetic Liability

Psychosocial and pharmacological treatments for cannabis use disorder and mental health comorbidities: a narrative review

2021 ◽  
pp. 1-12
Author(s):  
Rachel Lees ◽  
Lindsey A. Hines ◽  
Deepak Cyril D'Souza ◽  
George Stothart ◽  
Marta Di Forti ◽  
...  
Keyword(s):  
Mental Health ◽  
Clinical Decision Making ◽  
Treatment Compliance ◽  
Narrative Review ◽  
Cannabis Use ◽  
Psychotic Symptoms ◽  
Motivational Enhancement Therapy ◽  
Cannabis Use Disorder ◽  
Pharmacological Treatments ◽  
Health Comorbidities

Abstract Cannabis is the most widely used illicit drug worldwide, and it is estimated that up to 30% of people who use cannabis will develop a cannabis use disorder (CUD). Demand for treatment of CUD is increasing in almost every region of the world and cannabis use is highly comorbid with mental disorders, where sustained use can reduce treatment compliance and increase risk of relapse. In this narrative review, we outline evidence for psychosocial and pharmacological treatment strategies for CUD, both alone and when comorbid with psychosis, anxiety or depression. Psychosocial treatments such as cognitive behavioural therapy, motivational enhancement therapy and contingency management are currently the most effective strategy for treating CUD but are of limited benefit when comorbid with psychosis. Pharmacological treatments targeting the endocannabinoid system have the potential to reduce cannabis withdrawal and cannabis use in CUD. Mental health comorbidities including anxiety, depression and psychosis hinder effective treatment and should be addressed in treatment provision and clinical decision making to reduce the global burden of CUDs. Antipsychotic medication may decrease cannabis use and cannabis craving as well as psychotic symptoms in patients with CUD and psychosis. Targeted treatments for anxiety and depression when comorbid with CUD are feasible.

Sign in / Sign up

Export Citation Format

Share Document